Paper17536870
Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
Poli G and 6 others. Paediatr Drugs, 2007. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Papers, record 17536870. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17536870
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Cystic Fibrosis | Major topic |
| Pseudomonas Infections | Major topic |
| Tobramycin | Major topic |
| Administration, Inhalation | |
| Adolescent | |
| Adult | |
| Biological Availability | |
| Chronic Disease | |
| Cross-Over Studies | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Nebulizers and Vaporizers | |
| Particle Size | |
| Pseudomonas aeruginosa | |
| Therapeutic Equivalency |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9155846 | Current best practice for nebuliser treatment. The Nebulizer Project Group of the British Thoracic Society Standards of Care Committee. | Thorax | 1997 | https://conductscience.org/library/papers/9155846 | PubMed |
| 2 | 17536872 | A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. | Paediatr Drugs | 2007 | https://conductscience.org/library/papers/17536872 | PubMed |
| 3 | 3931522 | Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. | Am Rev Respir Dis | 1985 | https://conductscience.org/library/papers/3931522 | PubMed |
| 4 | 11555566 | Microbiological and immunologic considerations with aerosolized drug delivery. | Chest | 2001 | https://conductscience.org/library/papers/11555566 | PubMed |
| 5 | 14555458 | Pathophysiology and management of pulmonary infections in cystic fibrosis. | Am J Respir Crit Care Med | 2003 | https://conductscience.org/library/papers/14555458 | PubMed |
| 6 | 6696320 | Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. | Am Rev Respir Dis | 1984 | https://conductscience.org/library/papers/6696320 | PubMed |
| 7 | 11568993 | Efficacy and safety of aerosolized tobramycin in cystic fibrosis. | Pediatr Pulmonol | 2001 | https://conductscience.org/library/papers/11568993 | PubMed |
| 8 | 17224667 | Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. | Curr Opin Pediatr | 2007 | https://conductscience.org/library/papers/17224667 | PubMed |
| 9 | 9366574 | Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. | J Clin Invest | 1997 | https://conductscience.org/library/papers/9366574 | PubMed |
| 10 | 10678295 | Aerosolized antimicrobial therapy in acutely ill patients. | Pharmacotherapy | 2000 | https://conductscience.org/library/papers/10678295 | PubMed |
| 11 | 12114362 | Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. | Chest | 2002 | https://conductscience.org/library/papers/12114362 | PubMed |
| 12 | 16401680 | Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? | J Pediatr Psychol | 2006 | https://conductscience.org/library/papers/16401680 | PubMed |
| 13 | 8657217 | Management of pulmonary disease in patients with cystic fibrosis. | N Engl J Med | 1996 | https://conductscience.org/library/papers/8657217 | PubMed |
| 14 | 10492286 | Use of aerosolized antibiotics in patients with cystic fibrosis. | Chest | 1999 | https://conductscience.org/library/papers/10492286 | PubMed |
| 15 | 17536871 | Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. | Paediatr Drugs | 2007 | https://conductscience.org/library/papers/17536871 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36373968 | Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. | Cochrane Database Syst Rev | 2022 | https://conductscience.org/library/papers/36373968 | PubMed |
| 35914011 | Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. | Cochrane Database Syst Rev | 2022 | https://conductscience.org/library/papers/35914011 | PubMed |
| 33486720 | Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions. | Clin Pharmacokinet | 2021 | https://conductscience.org/library/papers/33486720 | PubMed |
| 31112621 | Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/31112621 | PubMed |
| 30376155 | Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. | Cochrane Database Syst Rev | 2018 | https://conductscience.org/library/papers/30376155 | PubMed |
| 29607494 | Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. | Cochrane Database Syst Rev | 2018 | https://conductscience.org/library/papers/29607494 | PubMed |
| 25893022 | Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis. | Open Respir Med J | 2015 | https://conductscience.org/library/papers/25893022 | PubMed |
| 22915944 | Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review. | Med Devices (Auckl) | 2011 | https://conductscience.org/library/papers/22915944 | PubMed |
| 17536872 | A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. | Paediatr Drugs | 2007 | https://conductscience.org/library/papers/17536872 | PubMed |
| 17536871 | Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. | Paediatr Drugs | 2007 | https://conductscience.org/library/papers/17536871 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17536870
GET https://conductscience.org/api/papers/v1/17536870/authors